IDXX

+ Watchlist + Portfolio

IDEXX Laboratories, Inc.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $562.20
52-Week Range: $518.55 – $769.98
Market Cap: $43.00B
P/E (TTM): 38.39
EPS (TTM): 14.22
Dividend Yield: —

Advanced Metrics

Price/Book: 26.70
PEG Ratio: 3.44
Return on Equity: 74.21%
Return on Assets: 27.08%
Gross Margin: 62.45%
Operating Margin: 34.98%
Profit Margin: 25.03%
Current Ratio: 1.17
Debt/Equity: 0.68
Total Debt: $1.10B
Free Cash Flow: $909.37M
Revenue Growth: 9.70%
Earnings Growth: 17.60%
Enterprise Value: $45.19B

IDXX Income statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Revenue	$3.37B	$3.66B	$3.90B	$4.30B
Cost of Revenue	$1.36B	$1.47B	$1.52B	$1.64B
Gross Profit	$2.00B	$2.19B	$2.38B	$2.66B
Research & Development	$254.82M	$190.95M	$219.79M	$251.21M
Selling, General & Admin	$850.75M	$901.89M	$1.03B	$1.05B
Operating Expenses	$1.11B	$1.09B	$1.25B	$1.30B
Operating Income	$898.76M	$1.10B	$1.13B	$1.36B
EBITDA	$1.01B	$1.22B	$1.27B	$1.51B
Pretax Income	$859.97M	$1.06B	$1.11B	$1.32B
Income Tax	$180.88M	$216.13M	$221.96M	$264.73M
Net Income	$679.09M	$845.04M	$887.87M	$1.06B
Diluted EPS	8.03	10.06	10.67	13.08
Diluted Shares	84.60M	83.98M	83.25M	81.03M

IDXX Balance Sheet statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Cash & Equivalents	$112.55M	$453.93M	$288.27M	$180.07M
Receivables	$490.90M	$529.53M	$561.32M	$693.19M
Inventory	$367.82M	$380.28M	$381.88M	$377.76M
Current Assets	$1.10B	$1.50B	$1.40B	$1.41B
Total Assets	$2.75B	$3.26B	$3.29B	$3.35B
Current Liabilities	$1.24B	$951.55M	$1.07B	$1.15B
Long-Term Debt	$694.39M	$622.88M	$449.79M	$374.84M
Total Debt	$1.47B	$1.07B	$986.95M	$976.06M
Total Liabilities	$2.14B	$1.78B	$1.70B	$1.75B
Retained Earnings	$3.60B	$4.44B	$5.33B	$6.39B
Shareholders' Equity	$608.74M	$1.48B	$1.60B	$1.61B
Working Capital	-$134.33M	$543.71M	$331.98M	$265.01M
Net Debt	$1.24B	$493.95M	$579.31M	$667.77M

IDXX Cash Flow statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Operating Cash Flow	$542.98M	$906.51M	$929.00M	$1.18B
Capital Expenditure	-$158.84M	-$133.63M	-$130.92M	-$138.23M
Free Cash Flow	$384.15M	$772.88M	$798.08M	$1.04B
Depreciation & Amortisation	$111.90M	$114.91M	$129.94M	$145.18M
Stock-Based Compensation	$49.77M	$59.74M	$60.30M	$60.01M
Investing Cash Flow	-$195.35M	-$125.25M	-$207.06M	-$136.24M
Financing Cash Flow	-$370.94M	-$442.00M	-$878.07M	-$1.16B
Share Repurchases	-$819.71M	-$71.92M	-$837.03M	-$1.22B
Net Change in Cash	-$23.30M	$339.26M	-$156.13M	-$119.40M

IDXX Income statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Revenue	$998.43M	$1.11B	$1.11B	$1.09B	$1.14B
Cost of Revenue	$375.05M	$414.73M	$421.88M	$432.46M	$418.08M
Gross Profit	$623.38M	$694.73M	$683.35M	$658.11M	$722.74M
Research & Development	$59.06M	$61.90M	$63.41M	$66.83M	$65.79M
Selling, General & Admin	$247.78M	$259.79M	$265.09M	$275.68M	$294.37M
Operating Expenses	$306.85M	$321.69M	$328.51M	$342.51M	$360.15M
Operating Income	$316.53M	$373.05M	$354.85M	$315.61M	$362.59M
EBITDA	$351.81M	$409.44M	$392.05M	$354.91M	$400.87M
Pretax Income	$310.08M	$362.35M	$344.77M	$306.98M	$355.44M
Income Tax	$67.41M	$68.36M	$70.16M	$58.79M	$77.00M
Net Income	$242.68M	$293.99M	$274.61M	$248.19M	$278.45M
Diluted EPS	2.96	3.63	3.40	3.08	3.47
Diluted Shares	81.92M	80.99M	80.67M	80.48M	80.16M

IDXX Balance Sheet statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Cash & Equivalents	$163.97M	$164.59M	$208.17M	$180.07M	$200.53M
Receivables	$604.15M	$663.47M	$714.97M	$693.19M	$697.21M
Inventory	$395.99M	$392.58M	$391.56M	$377.76M	$382.40M
Current Assets	$1.32B	$1.36B	$1.48B	$1.41B	$1.45B
Total Assets	$3.21B	$3.33B	$3.39B	$3.35B	$3.39B
Current Liabilities	$1.14B	$1.22B	$1.25B	$1.15B	$1.30B
Long-Term Debt	$449.80M	$449.81M	$374.82M	$374.84M	$299.85M
Total Debt	$1.06B	$1.24B	$1.11B	$976.06M	$1.11B
Total Liabilities	$1.77B	$1.87B	$1.83B	$1.75B	$1.83B
Retained Earnings	$5.58B	$5.87B	$6.14B	$6.39B	$6.67B
Shareholders' Equity	$1.45B	$1.46B	$1.56B	$1.61B	$1.56B
Working Capital	$181.40M	$138.48M	$225.24M	$265.01M	$154.22M
Net Debt	$776.26M	$939.21M	$771.66M	$667.77M	$779.32M

IDXX Cash Flow statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Operating Cash Flow	$237.96M	$185.74M	$402.34M	$355.76M	$266.25M
Capital Expenditure	-$30.03M	-$34.10M	-$44.46M	-$29.63M	-$33.78M
Free Cash Flow	$207.94M	$151.64M	$357.88M	$326.13M	$232.46M
Depreciation & Amortisation	$34.06M	$35.77M	$36.63M	$38.72M	$37.68M
Stock-Based Compensation	$14.62M	$14.85M	$14.43M	$16.11M	$16.34M
Investing Cash Flow	-$29.61M	-$33.63M	-$44.87M	-$28.13M	-$33.54M
Financing Cash Flow	-$330.32M	-$165.63M	-$313.31M	-$355.70M	-$211.43M
Share Repurchases	-$400.89M	-$338.11M	-$240.19M	-$237.77M	-$351.04M
Net Change in Cash	-$121.97M	-$13.52M	$44.16M	-$28.07M	$21.27M

Market Snapshot

About

IDEXX Laboratories, Inc. is a global leader in veterinary diagnostics, veterinary practice software, and water microbiology testing. The company develops, manufactures, and distributes products and services primarily for the companion animal veterinary, livestock and poultry, water testing, and dairy markets. IDEXX's companion animal diagnostic products include in-clinic laboratory analyzers, rapid assay tests, reference laboratory services, and practice management software used by veterinarians worldwide. The company holds a dominant market position in veterinary diagnostics with its comprehensive suite of instruments, consumables, software, and services. IDEXX serves customers in over 175 countries and has been a pioneer in point-of-care veterinary diagnostics for over three decades.